[{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ JMP Securities LLC"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ JMP Securities"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Vizient","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Vizient"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RP-2000","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TeraImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"TeraImmune","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Meloxicam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Not Applicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"TeraImmune","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Baudax Bio \/ Baudax Bio","highestDevelopmentStatusID":"5","companyTruncated":"Baudax Bio \/ Baudax Bio"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Undisclosed"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Baudax Bio \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Baudax Bio
Details :
TI-168 is the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.
Details :
The Company intends to use the net proceeds for pipeline development activities including, BX1000, an intermediate duration, clinical stage blocking agent, for neuromuscular blockade (NMB) in patients undergoing elective surgery.
Details :
The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
Details :
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or anot...
Details :
The Company intends to use the net proceeds from this offering for pipeline development activities, including BX1000, being developed for neuromuscular blockade (NMB) in patients undergoing elective surgery.
Details :
The Company intends to use the net proceeds from this offering for pipeline development activities including, Anjeso (meloxicam), a nonsteroidal anti-inflammatory drug (NSAID) to treat symptoms of Osteoarthritis, Rheumatoid Arthritis, and Moderate-to-Sev...
Details :
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or anot...
Details :
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or anot...
Details :
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or anot...
Details :
Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
Reset All
